Clinical TrialsNon-Small Cell Lung Cancer Clinical Trials 2022
Reviewed by Michael Gill, B. Sc.
25 Non Small Cell Lung Cancer Clinical Trials Near Me
Top Hospitals for Non Small Cell Lung Cancer Clinical Trials
Image of Massachusetts General Hospital in Massachusetts.
Massachusetts General Hospital
Boston
13Active Trials
111All Time Trials for Non Small Cell Lung Cancer
2003First Non Small Cell Lung Cancer Trial
Image of Dana-Farber Cancer Institute in Massachusetts.
Dana-Farber Cancer Institute
Boston
10Active Trials
77All Time Trials for Non Small Cell Lung Cancer
1994First Non Small Cell Lung Cancer Trial
Top Cities for Non Small Cell Lung Cancer Clinical Trials
Non-small Cell Lung Cancer Clinical Trials by Phase of Trial
Phase 1 Non-small Cell Lung Cancer Clinical Trials
20Active Non-small Cell Lung Cancer Clinical Trials
20Number of Unique Treatments
175Number of Active Locations
FurmonertinibSGN-PDL1VSGN-B7H4VPDR001Hyperpolarized xenon MRIPF-07284890CAN04Tremelimumab
Non-small Cell Lung Cancer Clinical Trials by Age Group
18+ Non-small Cell Lung Cancer Clinical Trials
91Active Non-small Cell Lung Cancer Clinical Trials
furmonertinib 160 mgMORAb-202 Dose 1CISH CRISPR TIL plus pembrolizumab / Phase I ArmAmivantamabLP-300AZD8853Furmonertinibpembrolizumab/vibostolimab
Most Recent Non Small Cell Lung Cancer Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
MORAb-202 Dose 1 for Carcinoma, Non-Small-Cell Lung
11/30/2022
Phase 2
Amivantamab for Carcinoma, Non-Small-Cell Lung
11/28/2022
Phase 2
CISH CRISPR TIL plus pembrolizumab / Phase I Arm for Squamous cell carcinoma
11/1/2022
Phase 1 & 2
SGN-PDL1V for Esophageal Squamous Cell Carcinoma
10/25/2022
Phase 1
POISE for Carcinoma, Non-Small-Cell Lung
10/1/2022
N/A
Top Treatments for Non Small Cell Lung Cancer Clinical Trials
Treatment Name
Active Non Small Cell Lung Cancer Clinical Trials
All Time Trials for Non Small Cell Lung Cancer
First Recorded Non Small Cell Lung Cancer Trial
Pembrolizumab
7
192
2011
Amivantamab
4
10
2016
Nivolumab
2
120
2011
Lazertinib
2
13
2016
CC-486
2
4
2011
Recently Completed Studies with FDA Approved Treatments for Non Small Cell Lung Cancer
Treatment
Year
Sponsor
Bosutinib
2019
Nagla Abdel Karim
canakinumab
2019
Novartis Pharmaceuticals
V941
2019
Merck Sharp & Dohme Corp.
M7824
2019
EMD Serono Research & Development Institute, Inc.
Docetaxel
2019
Novartis Pharmaceuticals
Retifanlimab
2019
Incyte Corporation
Ponatinib 15 MG
2018
Memorial Sloan Kettering Cancer Center
Exemestane
2018
Masonic Cancer Center, University of Minnesota
G1T38
2018
G1 Therapeutics, Inc.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: November 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.